PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Lannett Co's PE Ratio without NRI is 0.00. Lannett Co's 5-Year EBITDA growth rate is 0.00%. Therefore, Lannett Co's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Lannett Co's PEG Ratio or its related term are showing as below:
During the past 13 years, Lannett Co's highest PEG Ratio was 18.84. The lowest was 0.05. And the median was 0.31.
LCINQ's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.655 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Lannett Co PEG Ratio Historical Data
The historical data trend for Lannett Co's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lannett Co's PEG Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lannett Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Lannett Co's PEG Ratio falls into.
Lannett Co PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Lannett Co (OTCPK:LCINQ) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Lannett Co PEG Ratio Related Terms
Thank you for viewing the detailed overview of Lannett Co's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LCINQ has been successfully added to your 